CSN5在胃癌中的表达及与患者预后的相关性

doi:10.6040/j.issn.1671-7554.0.2016.1655

摘要/Abstract

摘要： 目的探讨CSN5在胃癌中的表达及与患者预后的关系。方法运用cBioportal分析工具,分析CSN5在胃癌中基因水平的改变情况;运用qRT-PCR方法检测CSN5 mRNA在永生化的正常胃黏膜细胞株及不同胃癌细胞株中的表达;运用Oncomine数据库(DErrico、Chen胃癌数据集)和TCGA数据库(375例胃癌组织和32例癌旁组织),分析CSN5 mRNA在胃癌组织与正常胃黏膜表达的差异性;运用生存期分析软件Kaplan-Meier plotter,分析CSN5对876例胃癌患者预后的影响;运用Chen胃癌数据集,分析胃癌患者5年生存状态与CSN5表达的关系。结果在胃癌中CSN5主要的基因改变形式为扩增;CSN5 mRNA在多种胃癌细胞株中的表达水平显著高于正常胃黏膜细胞株;CSN5 mRNA在胃癌中的表达显著高于正常胃黏膜。生存分析结果发现,CSN5高表达的患者总生存期较长,CSN5低表达的患者总生存期较短。结论 CSN5在胃癌组织中高表达,且其表达水平与胃癌患者的预后呈正相关,即CSN5高表达的患者,预后较好。

关键词: 胃癌, 组成型光形态发生因子9信号复合体, 预后

Abstract: Objective To investigate the expression of CSN5 in gastric carcinoma(GC)and to determine the prognostic value of CSN5 for GC patients. Methods The genomic alternation of CSN5 was assessed using cBioportal analytical tool. CSN5 mRNA expressions in normal gastric cell line and GC cell line were determined using qRT-PCR. The differences of CSN5 mRNA expressions in gastric mucosa and GC tissues were analyzed based on Oncomine database and TCGA database. The association between CSN5 and prognosis of GC patients was determined with Kaplan-Meier plotter. The relationship between CSN5 expression and 5-year survival of GC patients was analyzed using Chen gastric statistics. Results CSN5 was mainly amplified in GC. The mRNA expression of CSN5 was significantly higher in cancer cell lines than in normal gastric cell line, and was significantly higher in GC tissues than in normal gastric mucosa. Patients with high expression of CSN5 had longer overall survival(OS)than those with low expression. Conclusion The expression of CSN5 is elevated in GC tissues, which is also positively correlated with OS of GC patients.

Key words: Constitutive photomorphogenesis 9 signalosome, Prognosis, Gastric cancer

中图分类号:

R735.2

宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.

ZONG Shuai, XIAO Dongjie, LIU Hua, JIA Yanfei, MA Xiaoli, LI Huanjie, LI Ping, ZHENG Yan, WANG Yunshan. Expression of CSN5 and its correlation with the prognosis of gastric carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 12-16.

参考文献

[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Elimova E, Wadhwa R, Shiozaki H, et al. Molecular biomarkers in gastric cancer[J]. J Natl Compr Canc Netw, 2015, 13(4): e19-29.
[4] Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes[J]. Nat Med, 2015, 21(5): 449-456.
[5] Wei N, Deng XW. The COP9: a new genetic locus involved in light- regulated development and gene expression in arabidopsis[J]. Plant Cell, 1992, 4(12): 1507-1518.
[6] Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers[J]. J Clin Invest, 2011, 121(3): 851-865.
[7] Yang X, Menon S, Lykke-Andersen K, et al. The COP9 signalosome inhibits p27(kip1)degradation and impedes G1- S phase progression via deneddylation of SCF Cul1[J]. Curr Biol, 2002, 12(8): 667-672.
[8] Zhang XC, Chen J, Su CH, et al. Roles for CSN5 in control of p53/MDM2 activities[J]. J Cell Biochem, 2008, 103(4): 1219-1230.
[9] Xue Y, Chen J, Choi HH, et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53[J]. Cell Cycle, 2012, 11(22): 4181-4190.
[10] Fang L, Lu W, Choi HH, et al. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development[J]. Cancer Cell, 2015, 28(2): 183-197.
[11] Gao S, Fang L, Phan LM, et al. COP9 signalosome subunit 6(CSN6)regulates E6AP/UBE3A in cervical cancer[J].Oncotarget,2015,6(29):28026-28041. doi: 10.18632/oncotarget.4731.
[12] Li L, Deng XW. The COP9 signalosome: an alternative lid for the 26S proteasome?[J]. Trends Cell Biol, 2003, 13(10): 507-509.
[13] Kouvaraki MA, Rassidakis GZ, Tian L, et al. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1)[J]. Cancer Res, 2003, 63(11): 2977-2981.
[14] Sun L, Dong Y, Ohno M, et al. Jab1 expression is associated with inverse expression of p27(kip1)and poor prognosis in epithelial ovarian tumors[J]. Clin Cancer Res, 2001, 7(12): 4130-4135.
[15] Pan Y, Wang S, Su B, et al. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression[J]. Oncogene, 2017, 36(8): 1069-1079.
[16] Tomoda K, Kubota Y, Arata Y, et al. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex[J]. J Biol Chem, 2002, 277(3): 2302-2310.
[17] Pan Y, Zhang Q, Tian L, et al. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma[J]. Cancer Res, 2012, 72(7): 1890-1900.
[18] Sang MM, Du WQ, Zhang RY, et al. Suppression of CSN5 promotes the apoptosis of gastric cancer cells through regulating p53-related apoptotic pathways[J]. Bioorg Med Chem Lett, 2015, 25(15): 2897-2901.
[19] Duda DM, Borg LA, Scott DC, et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation[J]. Cell, 2008, 134(6): 995-1006.
[20] Gusmaroli G, Figueroa P, Serino G, et al. Role of the MPN subunits in COP9 signalosome assembly and activity, and their regulatory interaction with Arabidopsis Cullin3-based E3 ligases[J]. Plant Cell, 2007, 19(2): 564-581.
[21] Cope GA, Suh GS, Aravind L, et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1[J]. Science, 2002, 298(5593): 608-611.
[22] Dominguez-Sola D, Dalla-Favera R. PINning down the c-Myc oncoprotein[J]. Nat Cell Biol, 2004, 6(4): 288-289.
[23] Chen J, Shin JH, Zhao, et al. CSN6 drives carcinogenesis by positively regulating Myc stability[J]. Nat Commun, 2014, 5: 5384. doi: 10.1038/ncomms6384.
[24] Karlsson A, Deb-Basu D, Cherry A, et al. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression[J]. Proc Natl Acad Sci U S A, 2003, 100(17): 9974-9979.
[25] Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis[J]. Proc Natl Acad Sci U S A, 1999, 96(7): 3940-3944.
[26] Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins[J]. Nat Rev Mol Cell Biol, 2005, 6(8): 635-645.
[27] Guo H, Jing L, Cheng Y, et al. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis[J]. Hepatology, 2016, 63(3): 898-913.

相关文章 15

[1]	栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2]	史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3]	路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4]	李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[5]	孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[6]	董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[7]	林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[8]	周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[9]	张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[10]	刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.
[11]	李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报（医学版）, 2016, 54(8): 50-54.
[12]	王雯,刘尧,龙飞,马卫霞,苏莉莉. 外周血淋巴细胞/单核细胞比值与恶性胸膜间皮瘤患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(8): 72-77.
[13]	刘童,张欣,王传新. IRX5 mRNA在结直肠癌诊断及预后中的价值[J]. 山东大学学报（医学版）, 2016, 54(7): 69-74.
[14]	郝姝桦,郏雁飞,郑燕,马晓丽,孔毅,黎娉,宗帅,张垚,汪运山. ARNT2在胃癌中的表达及临床意义[J]. 山东大学学报（医学版）, 2016, 54(7): 6-10.
[15]	董秀红. 认知催眠疗法减轻胃癌化疗患者癌因性疲乏的疗效观察[J]. 山东大学学报（医学版）, 2016, 54(7): 56-59.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed